Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EBIT (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EBIT for 5 consecutive years, with $61.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 397.41% year-over-year to $61.2 million, compared with a TTM value of -$5.0 million through Dec 2025, up 94.37%, and an annual FY2025 reading of -$5.0 million, up 94.37% over the prior year.
  • EBIT was $61.2 million for Q4 2025 at Aligos Therapeutics, up from -$28.4 million in the prior quarter.
  • Across five years, EBIT topped out at $61.2 million in Q4 2025 and bottomed at -$37.9 million in Q4 2021.
  • Average EBIT over 5 years is -$20.4 million, with a median of -$22.4 million recorded in 2022.
  • Peak annual rise in EBIT hit 397.41% in 2025, while the deepest fall reached 40.88% in 2025.
  • Year by year, EBIT stood at -$37.9 million in 2021, then skyrocketed by 40.23% to -$22.7 million in 2022, then decreased by 14.62% to -$26.0 million in 2023, then grew by 20.9% to -$20.6 million in 2024, then soared by 397.41% to $61.2 million in 2025.
  • Business Quant data shows EBIT for ALGS at $61.2 million in Q4 2025, -$28.4 million in Q3 2025, and -$18.6 million in Q2 2025.